Dr. Ilyas Sahin, MD, is an oncologist at the Mass General Cancer Center, where he specializes in early-phase clinical trials and targeted therapies. With a career dedicated to advancing cancer treatments, Dr. Sahin’s work focuses on overcoming immunotherapy resistance and enhancing personalized medicine to address the unique needs of each patient.

At MGH, Dr. Sahin plays a key role in Phase 1 clinical trials, translating groundbreaking scientific discoveries into novel therapies for cancer patients. His research is particularly centered on targeted therapies and immunotherapies, aiming to push the boundaries of current treatment paradigms. Dr. Sahin has a strong clinical and research interest in Hepatocellular Carcinoma (HCC) as well as liver metastasis from other tumors. He is actively working on innovative treatments for liver metastasis, aiming to improve outcomes for patients with complex liver involvement from various cancers.

In addition to his research, Dr. Sahin is known for his compassionate and comprehensive approach to patient care. He integrates the latest scientific advances into tailored treatment plans, ensuring that each patient receives the most effective, evidence-based care possible.